THE ANALYSIS OF MULTIPLE END-POINTS IN CLINICAL-TRIALS

被引：385
|
作者：
POCOCK, SJ
GELLER, NL
TSIATIS, AA
机构：
[1] MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021
[2] HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115
来源：
BIOMETRICS | 1987年 / 43卷 / 03期
关键词：
D O I：
10.2307/2531989
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页码：487 / 498
页数：12
相关论文
共 50 条
  • [31] END-POINTS FOR VACCINE TRIALS - CONFERENCE SUMMARY
    ASCHER, MS
    SHEPPARD, HW
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 (10) : 1315 - 1316
  • [32] BIOMARKERS AS INTERMEDIATE END-POINTS IN CHEMOPREVENTION TRIALS
    LIPPMAN, SM
    LEE, JS
    LOTAN, R
    HITTELMAN, W
    WARGOVICH, MJ
    HONG, WK
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (07): : 555 - 560
  • [33] END-POINTS AND TRIALS - A MATTER OF LIFE AND DEATH
    ECTOR, H
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1994, 17 (06): : 1079 - 1081
  • [34] END-POINTS FOR MULTIMODAL CLINICAL-TRIALS IN STAGE-III NONSMALL CELL LUNG-CANCER (NSCLC) - A CONSENSUS REPORT
    GREEN, MR
    COX, JD
    ARDIZZONI, A
    ARRIAGADA, R
    BUREAU, G
    DARWISH, S
    DENEFFE, G
    FUKUOKA, M
    JOSEPH, D
    KOMAKI, R
    MIRIMANOFF, RO
    MORNEX, F
    PALAZZI, M
    PASTORINO, U
    PAVY, JJ
    POSTMUS, PE
    ROTH, J
    RUBIN, P
    SAIJO, N
    SAUNDERS, M
    STOUT, R
    SUTEDJA, TG
    TROVO, MG
    LUNG CANCER, 1994, 11 : S11 - S13
  • [35] EVALUATING THE ROLE OF CD4-LYMPHOCYTE COUNTS AS SURROGATE END-POINTS IN HUMAN-IMMUNODEFICIENCY-VIRUS CLINICAL-TRIALS
    LIN, DY
    FISCHL, MA
    SCHOERFELD, DA
    STATISTICS IN MEDICINE, 1994, 13 (18) : 1895 - 1896
  • [36] EVALUATING THE ROLE OF CD4-LYMPHOCYTE COUNTS AS SURROGATE END-POINTS IN HUMAN-IMMUNODEFICIENCY-VIRUS CLINICAL-TRIALS
    LIN, DY
    FISCHL, MA
    SCHOENFELD, DA
    STATISTICS IN MEDICINE, 1993, 12 (09) : 835 - 842
  • [37] Clinical effectiveness in cardiovascular trials in relation to the importance to the patient of the end-points measured
    Bowater, Russell J.
    Lilford, Richard J.
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2011, 17 (04) : 547 - 553
  • [38] DRUG TRIALS IN MIGRAINE - THE CLINICIAN VIEW ON END-POINTS
    BOUSSER, MG
    BARON, JC
    NEUROEPIDEMIOLOGY, 1987, 6 (04) : 228 - 233
  • [39] EVALUATING THE ROLE OF CD4-LYMPHOCYTE COUNTS AS SURROGATE END-POINTS IN HUMAN-IMMUNODEFICIENCY-VIRUS CLINICAL-TRIALS - REPLY
    LIN, DY
    STATISTICS IN MEDICINE, 1994, 13 (18) : 1896 - 1896
  • [40] DETERMINATION OF BIOMARKERS FOR INTERMEDIATE END-POINTS IN CHEMOPREVENTION TRIALS
    LEE, JS
    LIPPMAN, SM
    HONG, WK
    RO, JY
    KIM, SY
    LOTAN, R
    HITTELMAN, WN
    CANCER RESEARCH, 1992, 52 (09) : S2707 - S2710
12345